Last reviewed · How we verify

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) — Competitive Intelligence Brief

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) (tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine SARS-CoV-2 spike protein Immunology Live · refreshed every 30 min

Target snapshot

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) (tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) TARGET tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1 Pfizer marketed vaccine SARS-CoV-2 spike protein
Casirivimab and Imdevimab Drug Combination Casirivimab and Imdevimab Drug Combination Mansoura University Hospital marketed Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies) SARS-CoV-2 spike protein receptor-binding domain
COVID-19 vaccination COVID-19 vaccination University Medical Center Groningen marketed vaccine SARS-CoV-2 spike protein
The Pfizer mRNA-based BNT162b2 vaccine The Pfizer mRNA-based BNT162b2 vaccine dafna yahav marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine COVID-19 mRNA vaccine Vaccine Company, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
COMIRNATY intramuscular injection comirnaty-intramuscular-injection Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) — Competitive Intelligence Brief. https://druglandscape.com/ci/tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: